Friedman David Matthew reported grant involving 35,000 derivative units of Benitec Biopharma Inc. at $0.00 for $0 on May 26, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
35,000Options (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
35,000Direct
Trade date
May 26, 2026Grant
Filed
May 28, 2026, 9:10 PM ET3-day reporting delay
Accession
0001193125-26-245918Code A · Transaction 387519
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

BNTC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BNTC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +7%1w ago −7.3%1d ago −2.9%
Returns since7d −8.7%30d +7%90d +9.6%180d1y

Footnotes in full

F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. F2: The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027.